Genotyping and drug resistance patterns of Mycobacterium tuberculosis strains observed in a tuberculosis high-burden municipality in Northeast, Brazil

Luiz, Roberta dos Santos Silva; Suffys, Phillip Noel; E, Barroso; Kerr, Lígia Regina Franco Sansigolo; Duarte, Cynthia Romariz; Freitas, Max Victor Carioca; Mota, Rosa Maria Salani; Frota, Cristiane Cunha

doi:10.1016/j.bjid.2012.10.019

Cited by 14 publications

(11 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In current study, we have reported 29 % MDR-TB in presumptive drug resistant TB patients in Khyber Pakhtoonkhwa, which is similar to Liu et al finding as 30.4 % isolates were resistant to at least one first-line anti-TB drug [ 28 ]. Luiz et al reported 44.3 % isolates resistant to at least one first-line anti-TB drug in Brazil which is more than our findings [ 29 ]. Ullah et al [ 30 ] and Javaid et al [ 11 ] reported 11.5 and 11.3 % resistance to at least one anti-TB drug in different parts of Punjab, Pakistan.…”

Section: Discussioncontrasting

confidence: 69%

Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study

et al. 2016

View full text Add to dashboard Cite

BackgroundMulti-drug resistant tuberculosis (MDR-TB) is a major public health problem especially in developing countries. World Health Organization (WHO) recommends use of Xpert MTB/RIF assay to simultaneously detecting Mycobacterium tuberculosis (MTB) and rifampicin (RIF) resistance. The primary objective of this study was to determine the frequency of MDR-TB in patients suspected to have drug resistance in Khyber Pakhtunkhwa. The frequency of probes for various rpoB gene mutations using Xpert MTB/RIF assay within 81 bp RRDR (Rifampicin Resistance Determining Region) was the secondary objective.MethodsA total of 2391 specimens, received at Programmatic Management of Drug Resistant TB (PMDT) Unit, Lady Reading Hospital (LRH) Peshawar, Pakistan, between October 2011 and December 2014, were analyzed by Xpert MTB/RIF test. MTB positive with rifampicin resistance were further analyzed to first line anti-mycobacterial drug susceptibility testing (DST) using middle brook 7H10 medium. The data was analyzed using statistical software; SPSS version 18.ResultsOut of 2391 specimens, 1408 (59 %) were found positive for MTB and among them, 408 (29 %) showed rifampicin-resistance with four different rpoB gene mutations within 81 bp RRDR. The frequency of various probes among RIF-resistant isolates was observed as: probe E, in 314 out of 408 isolates; B, 44 out of 408; A, 5 out of 408; D, 34 out of 408; and probe C was observed among 6 out of 408 RIF-resistant isolates. The probe A&B and E&D mutation combination was found in only 1 isolate in each case, while B&D mutation combination was detected among 3 out of 408 RIF-resistant isolates.ConclusionsHence, it is concluded from our study on a selected population, 29 % of patients had MDR-TB. Probe E related mutations (also known as codon 531and 533) were the most common rpoB genetic mutation [314 (77 %)], acknowledged by Xpert MTB/RIF assay. Least mutation was detected within the sequence 511 (1.2 %).

show abstract

Section: Discussioncontrasting

confidence: 69%

Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…This study showed that most of the drug-resistant participants have not been previously treated (75.6%), and all the isolates presented mutation in the gyrA gene. The frequency of primary resistance was high in relation to that found in Brazil, in Ethiopia and Serbia [19][20][21] and lower than the one found in Bangladesh 22 . The cases of DR-TB were spread throughout the city, raising concern about the increase in the number of cases bearing primary resistant M. tuberculosis.…”

Section: Discussioncontrasting

confidence: 56%

Molecular characterization of pre-extensive drug resistant Mycobacterium tuberculosis in Northeast Brazil

Campelo

Lima

et al. 2020

Rev. Inst. Med. trop. S. Paulo

Self Cite

View full text Add to dashboard Cite

In Fortaleza, the capital of Ceara State, Brazil, the detection rate of tuberculosis (TB) in 2018 was 65.5/100,000 inhabitants with a cure rate of 59.1%, which is higher than the country average. This study investigated the risk factors associated with drug-resistant tuberculosis (DR-TB) and identified the drug-resistance phenotype and resistance-conferring mutations. The geographic distribution of DR-TB in Fortaleza, Brazil, was also determined. From March 2017 to February 2018, 41 DR-TB isolates and 69 drug-susceptible pulmonary TB isolates were obtained from patients seen at a referral hospital in Fortaleza, Brazil. Samples were subjected to phenotypic and genetic analysis of resistance; the spatial distribution of the participants was also analyzed. Primary resistance was high (50.9%) among participants. The following risk factors for DR were identified: being female (p = 0.03), having diabetes (p < 0.01), history of previous TB disease (p < 0.01), and the number of intra-domiciliary contacts (p < 0.01). Analysis by multiplex allele-specific polymerase chain reaction detected mutations in the genes katG (65.8%), rpoB (43.9%), inhA promoter (14.6%), and gyrA (9.8%). Sequencing identified mutations in the the genes katG (75.6%), inhA promoter (19.5%), rpoB (85.4%), and gyrA (100%). There was no mutation in the rrs gene. Spatial analysis showed DR-TB isolates distributed in areas of low socioeconomic status in the city of Fortaleza. Our results emphasized the importance of detecting resistance to TB drugs. The resistance found in the gene gyrA is of concern due to the high number of pre-extensive DR-TB cases in Fortaleza.

show abstract

“…Our findings were related to Liu et al (2013) as they reported the frequency of mycobacterium resistance to at least one of the first line drugs is 30.4% [17]. The conclusion of Luiz et al (2013) regarding mycobacterium resistance to at least one of the first line drugs in clinical isolates of Brazil was 44.3 %, these conclusions are higher than our findings [18]. Javaid et al (2008) and pointed the mycobacterium resistance as 11.3% and 11.5% to at least one of the first line drugs in clinical isolates of various regions of Pakistan.…”

Section: Discussionsupporting

confidence: 62%

Performance Evaluation of Xpert MTB/RIF Assay and Prevalence of rpoB Gene Mutation in <em> Mycobacterium Tuberculosis</em> in Clinical Isolates Quetta, Pakistan: A Cross Sectional Retrospective Cohort Study

Khan

Hidayatullah

et al. 2021

AJPNMS

View full text Add to dashboard Cite

With the use of Xpert assay, the detection mechanism of tuberculosis has completely transformed. Concurrently detecting mycobacterium and its resistance to rifampin (rif) which is also one of the primary marker for MDR-TB in addition to its surrogate activity against MTB in first line drugs. At large, resistance of mycobacterium strains against rifampicin is caused by rpoB gene mutations about 96.1 % globally while these mutations are generally situated at a site of 507-533rd residuals of amino acid in the rpoB gene of Mycobacterium, this region is also termed as Rifampicin resistance determining region (RRDR). In this study, we determined the mutations of various rpoB genes in different probes of 81 bp of RRD Region. A total of 6353 different specimens obtained at provincial reference laboratory of Fatima Jinnah general and chest hospital, Quetta (FJHQ), between Jan 2016 and Apr 2018 were examined by Xpert MTB/RIF assay. Altogether positive and negative samples for MTB were further examined with the light emitting diode (LED) fluorescence microscope. Pearson Chi square test was used to find out the associations between probe type and gender, treatment history and age group of the patients. Out of 6353 specimens 1297 MTB positive cases were detected by Xpert assay including 184 samples having both mycobacterium and RIF-resistance advised by mutations in 81 bp-RRD Region of rpoB gene which is further divided into five different probes. Further LED fluorescence microscope detected and confirmed 327 positive MTB samples out of 1297 specimens of Xpert assay. The associated probes mutation for rifampicin resistance were as follow: E (98/184), D (23/184), B (15/184), C (5/184), A (3/184), two probe mutation (5/184) in D&E (3/184) and C&D (2/184) and all probe mutation (35/184). The percentage of rpoB gene mutation in the studied population was 14.187 %. The commonest mutation associated with rpoB gene was in Probe E (53.2608%) also termed as 531 and 533 codons, additionally two probe mutation (2.7173%) in D&E (1.6304%) and C&D (1.0869%) and all probe mutation (19.0217%) were also detected that has never been detected before globally.

show abstract

Genotyping and drug resistance patterns of Mycobacterium tuberculosis strains observed in a tuberculosis high-burden municipality in Northeast, Brazil

Cited by 14 publications

References 31 publications

Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study

Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert MTB/RIF in Khyber Pakhtunkhwa, Pakistan: a retrospective study

Molecular characterization of pre-extensive drug resistant Mycobacterium tuberculosis in Northeast Brazil

Performance Evaluation of Xpert MTB/RIF Assay and Prevalence of rpoB Gene Mutation in <em> Mycobacterium Tuberculosis</em> in Clinical Isolates Quetta, Pakistan: A Cross Sectional Retrospective Cohort Study

Contact Info

Product

Resources

About